News
KPRX
1.940
-0.51%
-0.010
Kiora Pharmaceuticals Announces Chief Development Officer Resignation
TipRanks · 2d ago
Kiora Chief Development Officer Eric Daniels to depart April 17
Reuters · 2d ago
Weekly Report: what happened at KPRX last week (0323-0327)?
Weekly Report · 6d ago
Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX), Zentalis Pharmaceuticals (ZNTL) and Autolus Therapeutics (AUTL)
TipRanks · 03/27 16:30
Kiora Pharmaceuticals Q4 EPS $(1.60) Misses $(0.67) Estimate
Benzinga · 03/25 22:17
Kiora Pharmaceuticals GAAP EPS of -$2.64
Seeking Alpha · 03/25 11:12
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Reuters · 03/25 11:10
Kiora Pharmaceuticals FY2025 net loss widens 401% to $11 million; revenue drops to no revenue
Reuters · 03/25 11:03
KIORA PHARMACEUTICALS FY NET INCOME USD -10.8 MILLION
Reuters · 03/25 11:00
Weekly Report: what happened at KPRX last week (0316-0320)?
Weekly Report · 03/23 10:27
Weekly Report: what happened at KPRX last week (0309-0313)?
Weekly Report · 03/16 10:26
Weekly Report: what happened at KPRX last week (0302-0306)?
Weekly Report · 03/09 10:27
Weekly Report: what happened at KPRX last week (0223-0227)?
Weekly Report · 03/02 10:26
Clinical and Market Validation of Kiora’s Lead Programs Underpin Buy Rating and $12 Price Target
TipRanks · 02/26 08:25
Weekly Report: what happened at KPRX last week (0216-0220)?
Weekly Report · 02/23 10:26
Kiora Pharmaceuticals to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Reuters · 02/19 13:32
Weekly Report: what happened at KPRX last week (0209-0213)?
Weekly Report · 02/16 10:26
Weekly Report: what happened at KPRX last week (0202-0206)?
Weekly Report · 02/09 10:27
Weekly Report: what happened at KPRX last week (0126-0130)?
Weekly Report · 02/02 10:27
Weekly Report: what happened at KPRX last week (0119-0123)?
Weekly Report · 01/26 10:27
More
Webull provides a variety of real-time KPRX stock news. You can receive the latest news about KIORA PHARMACEUTICALS INC through multiple platforms. This information may help you make smarter investment decisions.
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.